En Carta Diagnostics develops molecular diagnostic technologies that enable the detection of DNA and RNA pathogens at the point of care.
En Carta Diagnostics has raised $3.4M in total funding. The most recent round was Seed. The last funding was announced in July 2026.
En Carta Diagnostics's investors include Blue Forest Ventures, Bpifrance, Ring Capital, CentraleSupélec Venture, 50 Partners Health.
En Carta Diagnostics is headquartered in Paris, France.
En Carta Diagnostics develops molecular diagnostic technologies that enable the detection of DNA and RNA pathogens at the point of care.
En Carta Diagnostics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"En Carta Diagnostics — Funding & Investors." VCBacked, July 10, 2026, https://www.vcbacked.co/company/en-carta-diagnostics. Accessed November 15, 2026.
VCBacked. (2026). En Carta Diagnostics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/en-carta-diagnostics
{{cite web |title=En Carta Diagnostics — Funding & Investors |url=https://www.vcbacked.co/company/en-carta-diagnostics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at En Carta Diagnostics? Request a listing update